Suppr超能文献

糖尿病相关蛋白PTP1B变构抑制剂设计的理论研究

Theoretical study on the design of allosteric inhibitors of diabetes associated protein PTP1B.

作者信息

Zhan Jiuyu, Liu Zhenyang, Gao Hongwei

机构信息

School of Life Science, Ludong University, Yantai, Shandong, China.

出版信息

Front Pharmacol. 2024 Aug 22;15:1423029. doi: 10.3389/fphar.2024.1423029. eCollection 2024.

Abstract

The protein tyrosine phosphatase 1B (PTP1B) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). Many PTP1B inhibitors have been reported, however, most of them lack high specificity and have adverse effects. Designing effective PTP1B inhibitors requires understanding the molecular mechanism of action between inhibitors and PTP1B. To this end, molecular dynamics (MD) simulations and molecular mechanics Poisson Boltzmann Surface Area (MM-PB/SA) methods were used to observe the binding patterns of compounds with similar pentacyclic triterpene parent ring structures but different inhibition abilities. Through structure and energy analysis, we found that the positions of cavities and substituents significantly affect combining capacity. Besides, we constructed a series of potential inhibitor molecules using LUDI and rational drug design methods. The ADMET module of Discovery Studio 2020 was used to predict the properties of these inhibitor molecules. Lastly, we obtained compounds with low toxicity and significant inhibitory activity. The study will contribute to the treatment of T2DM.

摘要

蛋白酪氨酸磷酸酶1B(PTP1B)是2型糖尿病(T2DM)的关键治疗靶点。虽然已经报道了许多PTP1B抑制剂,但其中大多数缺乏高特异性且具有副作用。设计有效的PTP1B抑制剂需要了解抑制剂与PTP1B之间的分子作用机制。为此,采用分子动力学(MD)模拟和分子力学泊松玻尔兹曼表面积(MM-PB/SA)方法,观察具有相似五环三萜母环结构但抑制能力不同的化合物的结合模式。通过结构和能量分析,我们发现空穴和取代基的位置显著影响结合能力。此外,我们使用LUDI和合理药物设计方法构建了一系列潜在的抑制剂分子。利用Discovery Studio 2020的ADMET模块预测这些抑制剂分子的性质。最后,我们获得了低毒性和显著抑制活性的化合物。该研究将有助于T2DM的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c53/11374740/81c493902463/fphar-15-1423029-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验